Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B

Ha, Nghiem B.; Ha, Nghi B.; Garcia, Ruel T.; Trinh, Huy N.; Chaung, Kevin T.; Nguyen, Huy; Nguyen, Khanh K.; Levitt, Brian S.; Nguyen, Mindie H.

doi:10.1007/s10620-011-1610-5

Cited by 52 publications

(40 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adherence to antiviral therapy is fundamental for the clinical management of patients with CHB [11,12]. Long-term viral suppression was found to be associated with histologic improvement in the reduction of fibrosis and ultimately regression of cirrhosis [13].…”

Section: Introductionmentioning

confidence: 99%

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Liu

Farazi

et al. 2018

Global Health Action

View full text Add to dashboard Cite

Background: Globally, of the 248 million people chronically infected with the hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) have been approved for the treatment of chronic hepatitis B (CHB) in China. Objectives: The aims of this study were to determine rates of adherence to NUC therapy in patients with CHB, to identify the self-perceived barriers to adherence, and to examine the factors associated with adherence. Methods: Questionnaire-based interviews were administered among Chinese patients with CHB at hepatology clinics of a tertiary hospital in the city of Wuhan, China. Adults aged 18 years or older prescribed with NUCs were recruited and interviewed to complete a 27-item questionnaire in a private setting, and adherence was measured using the Morisky Medication Adherence Scale (MMAS-8). Results: Among 369 participants, only 16.5% had high adherence (score of 8), 32.2% had medium adherence (score of 6 to <8), and 51.2% were measured with low adherence (score of <6). A logistic regression model was used to determine the factors associated with medication adherence. Significant predictors of high adherence consisted of urban residency, non-cirrhotic status, not using prescribed pills other than HBV medications, and reminders from family members. The five most common reasons for skipping NUCs were that medication(s) are expensive (48.7%), forgetfulness (45.1%), have experienced or worry about potential side effects (19.8%), do not want others to know about my medication(s) usage (18.5%), and ran out of pills and do not have time to refill (15.9%). Conclusions: This study revealed that adherence rates to oral antiviral therapy were far from optimal. This finding should generate public attention, and it would be beneficial for interventional programs to target Chinese patients from rural regions, as well as patients with low socioeconomic status, cirrhosis, and taking multiple medications.

show abstract

Section: Introductionmentioning

confidence: 99%

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Liu

Farazi

et al. 2018

Global Health Action

View full text Add to dashboard Cite

show abstract

“…5 Non-adherence has been reported to be between 10% and 15% based on studies in community and academic settings. 6,7 Toy et al used a Markov model to evaluate the long-term outcomes for chronic hepatitis B patients. They found either entecavir or tenofovir monotherapy could lead to significantly improved qualityadjusted life years (5.5-12.1) and reported cost-effectiveness if implemented in China at a population level.…”

Section: Acknowledgementmentioning

confidence: 99%

Letter: reduction in chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low‐risk patients – more questions than answers. Authors' reply

Lin

Yang

Hoang

et al. 2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A presença de mutações na polimerase do HBV origina a resistência genotípica, que pode ser comprovada através do sequenciamento direto dos produtos da reação do PCR (98)(99)(100)(101)(102) .…”

Section: A Adesão Ao Tratamento Na Hepatite B Crônicaunclassified

Avaliação dos desfechos virológicos e de adesão ao tratamento antiviral em pacientes portadores de hepatite B crônica

Abreu¹

View full text Add to dashboard Cite

Ao Prof. Dr. Raymond Schinazi, que aceitou coorientar essa pesquisa e recebeu-me em seu laboratório na Emory University por seis meses, em Atlanta -EUA. Foi uma honra trabalhar com ele durante esse período e fazer parte do seu grupo. Em especial, gostaria de agradecer à Profa. Dra. Leda Bassit, por seus ensinamentos e orientações, imprescindíveis para a realização desse trabalho. À Dra. Lilia Ganova-Raeva e ao Dr. Yury Khudyakov (Centers for Disease Control and Prevention -EUA), agradeço pela valiosa ajuda em biologia molecular e apoio ao projeto. Aos pacientes, principal motivação desta pesquisa."A doença é o lado escuro da vida, uma cidadania mais onerosa. Todos que nascemos temos essa dupla cidadania, no reino da saúde e no reino da doença. Embora todos gostaríamos de usar só o bom passaporte, mais cedo ou mais tarde, cada um de nós é obrigado, pelo menos por um tempo, a se identificar como cidadãos daquele outro lugar." Susan Sontag, .

show abstract

Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B

Cited by 52 publications

References 33 publications

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Letter: reduction in chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low‐risk patients – more questions than answers. Authors' reply

Avaliação dos desfechos virológicos e de adesão ao tratamento antiviral em pacientes portadores de hepatite B crônica

Contact Info

Product

Resources

About